HSPG2 and Alzheimer disease: Perlecan domain V is neuroprotective, and has anti-inflammatory properties leading to the proposal of domain-V for the treatment of Alzheimer’s disease (AD), stroke patients (Lee et al., 2011; Clarke et al., 2012; Kahle et al., 2012; Bix, 2013; Bix et al., 2013; Guell and Bix, 2014; Marcelo and Bix, 2014; Edwards and Bix, 2019a; Edwards and Bix, 2019b), vascular dementia (Marcelo and Bix, 2015) and brain trauma (Badaut and Bix, 2014).